

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10693377
	Filing Date		2003-10-24
	First Named Inventor	James Hunter Boone	
	Art Unit	1645	
	Examiner Name	Virginia Allen Portner	
	Attorney Docket Number	TLAB.100292	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5681699	A	1997-10-28	Rotlier et al.	
	2	5691151	A	1997-11-25	Braun	
	3	5874233	A	1999-02-23	Targan et al.	
	4	5916748	A	1999-06-29	Targan et al.	
	5	6074835	A	2000-06-13	Braun et al.	
	6	6174664	B1	2001-01-16	Heine	
	7	6537768	B1	2003-03-25	Braun	
	8	6562629	B1	2003-05-13	Lin	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10693377
Filing Date	2003-10-24
First Named Inventor	James Hunter Boone
Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	TLAB.100292

9	6667160	B2	2003-12-23	Fine	
10	6818181	B2	2004-11-16	Lee	
11	6884625	B2	2005-04-26	Lee	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
1		20020168286		2002-11-14	Middeldorp et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1		0615129	EP		1994-09-14	Targan		<input type="checkbox"/>
2		0111334	WO		2001-02-15	Lin		<input type="checkbox"/>
3		9739356	WO		1997-10-23	Targan		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10693377
Filing Date	2003-10-24
First Named Inventor	James Hunter Boone
Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	TLAB.100292

4	9846997	WO		1998-10-22	Plevy		<input type="checkbox"/>
---	---------	----	--	------------	-------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁹
	1	Armitage & Colton, RANDOM SAMPLE, Encyclopedia of Biostatistics, John Wiley & Sons (1998), Vol. 5, p. 3686.	<input type="checkbox"/>
	2	Armitage & Colton, SAMPLING DISTRIBUTION, Encyclopedia of Biostatistics, John Wiley & Sons (1998), Vol. 5, pp. 3933-3935.	<input type="checkbox"/>
	3	Armitage & Colton, SAMPLING FRAMES, Encyclopedia of Biostatistics, John Wiley & Sons (1998), Vol. 5, pp. 3935-3939.	<input type="checkbox"/>
	4	Armitage & Colton, SELECTION BIAS, Encyclopedia of Biostatistics, John Wiley & Sons (1998), Vol. 5, p. 4045.	<input type="checkbox"/>
	5	DARROCH C J; BARNES R M R; DAWSON J Journal of Clinical Pathology, 19990101 BMJ Publishing Group - ISSN 0021-9746 Vol:52, Nr:1, Page(s):47 - 53.	<input type="checkbox"/>
	6	Database Biosis [Online] Biosciences Information Service, Philadelphia, PA; 2002, Ledis Pierenrico, et al.: "[p-ANCA and ASCA Antibodies and the Differential Diagnosis Between Ulcerative Colitis and Crohn's Disease]", Recent Progress In Medicina, Vol. 93, No.5, 2002.	<input type="checkbox"/>
	7	Database CAPLUS on STN, AN 2003:463137. KANE et al. 'Fecal Lactoferrin is a sensitive and specific marker in identifying intestinal inflammation' American J. Gastroenterology, 2003, Vol. 98, No 6, page 1309-1314. See Abstract, particularly the high specificity of the neutrophil marker in detecting patients.	<input type="checkbox"/>
	8	Esaguy, N. et al. Mycobacteria and human autoimmune disease: direct evidence of cross-reactivity between human lactoferrin and the 65-kilodalton protein of tubercle and leprosy bacilli. INFECTION & IMMUNITY. 1991 ;59:1117-1125.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10693377
Filing Date	2003-10-24
First Named Inventor	James Hunter Boone
Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	TLAB.100292

9	Ferguson, A. et al. Technical report: results of immunological tests on faecal extracts are likely to be extremely misleading. CLIN. EXP. IMMUNOL. 1995;99:70-75.	<input type="checkbox"/>
10	Functional Colonic Diseases, MeSH Database, National Library of Medicine & National Institutes of Health, available at http://www.ncbi.nlm.gov . 1 page total.	<input type="checkbox"/>
11	HCAPLUS Abstract of US 6667160 (one page).	<input type="checkbox"/>
12	Inflammatory Bowel Diseases, MeSH Database, National Library of Medicine & National Institutes of Health, available at http://www.ncbi.nlm.gov . 2 pages total.	<input type="checkbox"/>
13	KAPEL N; ET AL EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 19920401 WALTER DE GRUYTER, BERLIN, DE - ISSN 0939-4974 Vol:30, Page(s): 197 - 202.	<input type="checkbox"/>
14	Kruzel et al. (Advances in Experimental Medicine and Biology, 1998, 443, pp. 167-173- Abstract Only). cited by examiner .	<input type="checkbox"/>
15	Mayet, W.J. et al. The pathophysiology of anti-neutrophil cytoplasmic antibodies (ANCA) and their clinical relevance. CRIT. REV. ONCOL. HEMATOL. 1996;23:151-165.	<input type="checkbox"/>
16	MEILLET D; ET AL CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 19870101 Wiley-Blackwell Publishing Ltd, GB - ISSN 0009-9104 Vol:69, Page(s):142 - 147.	<input type="checkbox"/>
17	O'Mahony, S. et al. Appraisal of gut lavage in the study of intestinal humoral immunity. GUT. 1990;31 :1341-1344.	<input type="checkbox"/>
18	Picarelli, A. et al. Antidendomyosial antibody detection in fecal supernatants: In vivo proof that small bowel mucosa is the site of antidendomyosial antibody production. AM. J. GASTROENTEROL. 2002;97:95-98.	<input type="checkbox"/>
19	Roozendaal, C., et al.: "Are Anti-Neutrophil Cytoplasmic Antibodies (ANCA) Clinically Useful in Inflammatory Bowel Disease (IBD)?" Clinical and Experimental Immunology, Oxford, GB, Vol. 116, No. 2, May 1999 (1999-05).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10693377
Filing Date	2003-10-24
First Named Inventor	James Hunter Boone
Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	TLAB.100292

20	Sanders, D.S. et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. LANCET 2001 ;358: 1504-1508.	<input type="checkbox"/>
21	Sugi, K., Saitoh, O., Hirata, I., and K. Katsu. 1996. Fecal Lactoferrin as a Marker for Disease Activity in Inflammatory Bowel Disease. Comparison with Other Neutrophil-derived Proteins. Amer. J. Gastroenterol. 91:927-934.	<input type="checkbox"/>
22	Tibble, J., Teahon, K., Thjodleifsson, B., et al., "A Simple Method for Assessing Intestinal Inflammation in Crohn's Disease" Gut 2000;47-506-513.	<input type="checkbox"/>
23	Tibble, J.A. and Bjarnason, I., "Non-Invasive Investigation of Inflammatory Bowel Disease" World J Gastroenterol, 2001;7(4):460-465.	<input type="checkbox"/>
24	US Application No. 10/693,377; Filed: 2003-10-24; USPTO Office Action Mailed: 2006-09-05.	<input type="checkbox"/>
25	US Application No. 10/693,377; Filed: 2003-10-24; USPTO Office Action Mailed: 2007-02-22.	<input type="checkbox"/>
26	US Application No. 10/693,377; Filed: 2003-10-24; USPTO Office Action Mailed: 2007-09-25.	<input type="checkbox"/>
27	US Application No. 10/693,377; Filed: 2003-10-24; USPTO Office Action Mailed: 2007-11-01.	<input type="checkbox"/>
28	USPTO Final Office Action mailed Jan. 26, 2007 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>
29	USPTO Nonfinal Office Action mailed Aug. 9, 2006 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>
30	USPTO Nonfinal Office Action mailed June 3, 2009 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10693377
Filing Date	2003-10-24
First Named Inventor	James Hunter Boone
Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	TLAB.100292

31	USPTO Nonfinal Office Action mailed May 17, 2005 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>
32	USPTO Nonfinal Office Action mailed Nov. 21, 2005 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>
33	USPTO Nonfinal Office Action mailed Oct. 4, 2007 for US Patent Application Serial No. 10/656,034, filed Sept. 5, 2003.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.